In agreement with the PI3K-AKT-mTOR pathway is pivotal in activating aerobic glycolysis, CD19-CAR-T cells have remarkable central-memory phenotypes and more robust tumor elimination efficacy when treated with AKT inhibitors (Klebanoff et al., 2017). The gene discussed is AKT1; the disease is neoplasm.